GlassScriptPhysician profile
Olatomide Familusi
NPI 1053766352
$6,997.49
in general payments reported to CMS, 2019-2025
9 companies · $4,784 in 2025
The $4,784 reported for 2025 was more than what 92% of Plastic Surgery providers received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,452 · 2022: $151 · 2023: $127 · 2024: $484 · 2025: $4,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,793 · Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,793.32 |
| Food and Beverage | $2,601.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $2,631.97 | 2025 | |
| Abbvie INC. | $1,763.47 | 2023-2025 | |
| Allergan, INC. | $1,452.01 | 2021 | |
| Mentor Worldwide LLC | $796.94 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 4 Breast Tissue Expander, Mentor Siltex Round Spectrum |
| Integra Lifesciences Corporation | $187.44 | 2022-2025 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Acera Surgical, INC. | $96.25 | 2024 | Restrata Wound Matrix |
| Revance Therapeutics, INC. | $34.46 | 2024 | Daxxify |
| Lemaitre Vascular, INC. | $20.95 | 2023 | Anastoclip Gc 8cm (Medium) |
| Galderma Laboratories, L.P. | $14.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olatomide Familusi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.